February 2025
1. SIVAGURUNATHAN K, Jegathesan N
   Hypothyroid Myopathy with Muscle Pseudohypertrophy.
   N Engl J Med. 2025;392:599.
   

   >> Share

   
   April 2024
2. ALLEGRETTI AS, Czawlytko CL, Stathatos N, Sadow PM, et al
   Case 13-2024: A 27-Year-Old Man with Leg Weakness.
   N Engl J Med. 2024;390:1514-1522.
   

   >> Share

   
   February 2024
3. DHAR R, Marklin GF
   Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors. Reply.
   N Engl J Med. 2024;390:575-576.
   

   >> Share

   
   
4. ROCCHETTI NS, Vilches-Arenas A, Egea-Guerrero JJ
   Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.
   N Engl J Med. 2024;390:575.
   

   >> Share

   
   
5. MALONE JR
   Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.
   N Engl J Med. 2024;390:574-575.
   

   >> Share

   
   
6. CUSI K
   Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
   N Engl J Med. 2024;390:559-561.
   

   >> Share

   
   December 2023
7. ARJUNAN D, Bhadada SK
   Thyroid Dermopathy in Graves' Disease.
   N Engl J Med. 2023;389:2376.
   

   >> Share

   
   November 2023
8. DHAR R, Marklin GF, Klinkenberg WD, Wang J, et al
   Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.
   N Engl J Med. 2023;389:2029-2038.
   

   >> Share

   
   
9. CASTINETTI F, Borson-Chazot F
   Thirty Years of Progress Thanks to the RET Oncogene.
   N Engl J Med. 2023;389:1916-1918.
   

   >> Share

   
   
10. SVENNBERG E
    What Lies beneath the Surface - Treatment of Subclinical Atrial Fibrillation.
    N Engl J Med. 2023 Nov 12. doi: 10.1056/NEJMe2311558.
    

    >> Share

    
    October 2023
11. HADOUX J, Elisei R, Brose MS, Hoff AO, et al
    Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
    N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2309719.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share